Disitamab ELISA Kit (DY286018)

Datasheet Compartir producto Copiar información

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	DY286018
Tipo de muestra	Plasma, Serum
Sensibilidad	0.156 μg/ml
Rango	0.31-5 μg/mL
Número de acceso	P04626
Aplicaciones	ELISA
Método de detección	Colorimetric
Tipo de ensayo	Quantitative
Recuperación	80-120%
Envío	2-8 ℃
Estabilidad y almacenamiento	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Especificaciones	Disitamab
Nombres alternativos	RC48-0, Disitamab Vedotin, 2185868-98-6
Fondo	Receptor tyrosine-protein kinase erbB-2 (Disitamab) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane.
Referencias	1. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935. [DY286018] 2. Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. [DY286018] 3. Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61. [DY286018]
Nota	For Research Use Only.